23.01.2013 - Merck-Serono spin-out Prexton Therapeutics has secured an exclusive licence option on a Parkinson candidate of Domain Therapeutics.
The Strasbourg-based company's metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) was previously developed through a licensing and collaboration agreement signed between Domain and Merck Serono in January 2011. Prexton was spun out following Merck Serono restructuring, taking on the mother company's R&D portfolio in the field of Parkinson's disease.
Under the terms of the agreement signed between Domain and Prexton, Prexton will benefit from an exclusive license option to progress two mGluR4 PAM drug candidates into clinical development. mGluR4 is a glutamate receptor, member of the G-Protein Coupled Receptor (GPCR) family and is believed to be a potential therapeutic target for Parkinson’s disease. Allosteric modulation of mGluR4 receptors is thought to exert regulatory activity onglutamate-mediated neurotransmission
16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.
14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.
31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.
31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.